As we get closer to the end of the financial year I reflect on what to expect in the short term.
From what I have heard and read in announcements and interviews I feel we have receive guidance to expect the following by end Dec 2018:
US partnership for Vivagel BV expected;
Fleurstat Launch expected;
FDA response for Vivagel BV expected;
AZD0466 possibility to enter Phase 1 clinical trials; and
DEP Irinotecan to enter Phase 1 clinical trials.
5 key announcments over a 7 month period until the end of the year looks truly amazing to me.
I do not expect a $2 share price but I also dont rule out is possibility, I realistically would expect to hit our 12 month high however.
I finished investing in Starpharma at $1.215 a couple of days ago and feel pretty comfortable about it considering the announcments expected.
If anybody can explain why we would not hit any of these announcments i'd read your post in great detail and provide no criticism. I look forward to your insights/opinions.
The current share price looks attractive to me however i'm already all in.
SPL Price at posting:
$1.19 Sentiment: Buy Disclosure: Held
